I was six years old when open heart surgery saved my brother’s life. It was the first of many times when I thought about becoming a doctor, so that I, too, could save someone’s life. For more than 26 years, I’ve had that opportunity. I’ve treated more than 5,000 patients who’ve had prostate cancer and are now thriving after having their prostate gland removed through a procedure known as radical prostatectomy.
I came to NYU Langone in 1993, because I had a tremendous opportunity to build a world-class urology department here. Since then, our department has defined state-of-the-art care by improving outcomes for radical prostatectomy. For example, we now use a technique that spares the nerves, preserving function as much as possible.
We have also pioneered the use of MRI to diagnose and pinpoint the precise location of prostate cancer. More than 90 percent of patients who’ve needed surgery to remove the prostate at NYU Langone have reported long-term satisfaction with the outcomes.
We are at the forefront of research into prostate cancer, using image-guided diagnostic techniques, such as MRI, to help us determine the best treatment—whether it’s surveillance of slow-growing cancer, the need for complete removal of the prostate, or destroying one malignant area without using surgery.
It's the connection we make with patients and their families that humanizes medicine in this age of technology. For this reason, I take the time to listen to my patients and guide them through treatment, every step of the way.
Conditions and Treatments
- Professor, Department of Urology
- Professor, Department of Biochemistry and Molecular Pharmacology
- Martin Spatz Chair Dept of Urology
- Urology Chief
- AB Urology - Urology
Education and Training
- Residency, Johns Hopkins Hospital
- Residency, Johns Hopkins Hospital
- MD from Johns Hopkins University
Locations and Appointments
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Healthy NY
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
- HealthSmart (WTC)
- MultiPlan/PHCS PPO
- Oxford Exchange
- Oxford Freedom
- Oxford Liberty
- United Exchange- Compass
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
“We have worked to improve the technique for removing the prostate, preserving as many nerves as possible.”Herbert Lepor, MD Urologist
Neuropharmacology and Physiology of the ProstateWe characterize the neuropharmacology and neurophysiology of the prostate. Thus far, we have characterized the alpha1, alpha2, muscarinic cholinergic, DHP, and endothelin receptors in the prostate using radioligand receptor-binding studies. Additionally, we determined the cellular localization and physiological role of these receptors using autoradiography, isometric tension studies, and in vivo studies. Recently, we characterized and localized the alpha1 adrenoceptor subtypes in the human prostate. The clinical relevance of these investigations relates to the management of benign prostatic hyperplasia (BPH), a very common disease that causes bladder dysfunction and lower urinary tract symptoms in the aging male population. Bladder outlet obstructions secondary to BPH appear to be an important factor in the pathophysiology of the disease process. Alpha1 antagonists are routinely used to treat BPH. The tension of prostate smooth muscle is mediated by the alpha1 endothelin receptors and nitric oxide. In future investigations, we will study the role of endothelin antagonists and nitric oxide agonists.
Optimization of Prostate Biopsy: The Role of MRI Targeted Biopsy in Detection, Localization, and Risk AssessmentBjurlin, Marc A; Meng, Xiaosong; Le Nobin, Julien; Wysock, James S; Lepor, Herbert; Rosenkrantz, Andrew B; Taneja, Samir S 2014 Apr; 85-105, Journal of urology — id: 931792, year: 2014, page: 85, stat: REVIEW
Your Guide to Making Prostate Cancer Treatment DecisionsLamm, Steven; Lepor, Herbert; Sperling, Dan 2014 Jan-Feb; 12-13, Coping with cancer — id: 824942, year: 2014, page: 12
Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cellsLee, Hyun-Wook; Wang, Hsiang-Tsui; Weng, Mao-Wen; Hu, Yu; Chen, Wei-Sheng; Chou, David; Liu, Yan; Donin, Nicholas; Huang, William C; Lepor, Herbert; Wu, Xue-Ru; Wang, Hailin; Beland, Frederick A; Tang, Moon-Shong 2014 May; 67-67, Oncotarget — id: 1036762, year: 2014, page: 67, stat: JOURNAL ARTICLE